



**Media Contact:**

Ian Stone or David Schull

Russo Partners

Tel: +1 619-528-2220

[ian.stone@russopartnersllc.com](mailto:ian.stone@russopartnersllc.com)

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

**Alder Biopharmaceuticals Appoints Bruce Montgomery to Board of Directors**

BOTHELL, Wash., Nov. 1, 2010 – Alder Biopharmaceuticals Inc. today announced that it has appointed A. Bruce Montgomery, M.D., to the company’s board of directors.

Dr. Montgomery, 57, served as founder and chief executive officer of Corus Pharmaceuticals from 2001 through its acquisition in 2006 by Gilead Sciences. While at Gilead, he served as Senior Vice President and Head of Respiratory Therapeutics where he successfully led the approval of Cayston (aztreonam) as a treatment to improve respiratory symptoms in cystic fibrosis patients with *Pseudomonas aeruginosa*. He previously held positions in clinical development with PathoGenesis and Genentech. Dr. Montgomery recently served on the board of directors for Zymogenetics and is a trustee of the Washington State Life Sciences Fund.

“Bruce brings a wealth of global pharmaceutical and biotechnology industry experience to the Alder board including his involvement with a number of drug approvals,” said Randall Schatzman, president and chief executive officer of Alder Biopharmaceuticals. “We look forward to his contributions as Alder continues to grow its pipeline of clinical assets and move ALD518 through clinical studies in cancer, cancer anemia and cancer supportive care.”

Dr. Montgomery received a bachelor’s degree in chemistry and a doctorate from University of Washington. He completed postgraduate training at University of Washington and University of California, San Francisco.

**About Alder Biopharmaceuticals**

Alder Biopharmaceuticals Inc. [uniquely identifies](#), develops and [manufactures](#) novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder’s management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the

out-licensing of its technologies. In addition to Bristol-Myers Squibb, partners include Merck (Schering-Plough), Seattle Genetics and Genmab. For more information, visit [www.alderbio.com](http://www.alderbio.com).

Editor's Note: Photograph available on request